Literature DB >> 36137892

Sexually-transmitted monkeypox: report of two cases.

Paula Sian Lopes1, Gabriela Roncada Haddad2, Hélio Amante Miot3.   

Abstract

Monkeypox is an emerging infection that has spread to all continents since May 2022. It is caused by the zoonotic monkeypox virus, consisting of double-stranded DNA, belonging to the Orthopoxvirus genus of the Poxviridae family, which has high transmissibility, especially by contact with the skin, favoring its sexual transmission. This case report describes a same-sex male couple, both aged 28 years old, without comorbidities. In the index case, perioral and penile lesions started ten days before the consultation, with rapid progression and a high fever that started eight days after the appearance of the lesions. In the second case, the perioral lesions started three days after the partner; however, he remained afebrile. Both were isolated, treated with symptomatic measures, and, after ulceration, the lesions completely regressed in 14 days. Dermatologists should be aware of manifestations of monkeypox, which may include vesiculopustular lesions in areas of sexual contact, as well as oligosymptomatic cases or cases with few skin lesions.
Copyright © 2022 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Monkeypox; Sexually transmitted diseases; Sexually transmitted diseases, viral

Mesh:

Year:  2022        PMID: 36137892      PMCID: PMC9560761          DOI: 10.1016/j.abd.2022.08.002

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   2.113


In July/2022, the World Health Organization declared monkeypox (MP) a public health emergency of international importance, as cases have been reported in more than 80 countries, on all continents. At the beginning of August/2022, more than 2,100 cases, among adults and children, and one death in an immunosuppressed patient, were confirmed in Brazil. The monkeypox virus is an enveloped double-stranded DNA zoonotic virus that belongs to the genus Orthopoxvirus and the family Poxviridae. Sporadic outbreaks of MP have been reported in Africa since the 1970s, usually originating from contact with wildlife reservoirs, being currently endemic in sub-Saharan communities. With the eradication of smallpox (1980) and the discontinuation of vaccination, the world’s population became susceptible to zoonotic poxvirus infections, and MP emerged as a public health problem due to its high rate of contagion.2, 3, 4 MP has three stages in humans: incubation (seven to 14 days); general symptoms and rash.5, 6 The initial symptoms include fever, headache, asthenia, myalgia, and lymphadenopathy. After one to five days, a maculopapular rash appears, with centrifugal distribution. Lesions are 0.5‒1 cm in diameter and can range from a few and local to thousands, synchronously developing into four phases (macular, papular, and vesiculopustular with central umbilication, before ulcerating and resolving in 14–21 days). MP transmission can occur through large respiratory droplets, contact, and possibly contaminated fomites. However, it mainly occurs through contact with the lesions on the skin, and the most recent cases have occurred in men who have sex with men. Perineal and genital lesions suggest transmission by sexual intercourse and may be confused with herpes simplex, molluscum contagiosum, or syphilis.2, 5 Patient isolation should be maintained for 14–21 days and isolation of close contacts for 14 days. The risk factors for MP include being a young male, and risk behaviors such as sexual activity without a condom, with many partners, and a history of sexually transmitted infections.4, 6, 7 This case report describes a same-sex male couple, who showed all these risk factors and developed sexually transmitted MP.

Index case

A 28-year-old male patient reported “a sore” in the corner of the mouth for ten days, with rapid progression, accompanied by cervical lymphadenopathy, myalgia, headache, and fever (39 °C) eight days after the initial appearance of the lesion. He reported having sex with other partners without a condom, or the regular use of pre-exposure prophylaxis to prevent HIV infection. He also mentioned effective treatment for latent syphilis two months before. On examination, he was apathetic, had an ulcero-crusted lesion, with active vesiculopustular borders, measuring 1.5 cm on the rima oris, with a necrotic, exudative background, and local erythema (Fig. 1 ), besides painful and hardened cervical and supraclavicular lymphadenopathy, measuring 2 cm in diameter. He also had three umbilicated pustules measuring 3 mm on the shaft of the penis, and inguinal lymphadenopathy (Fig. 2 ).
Figure 1

Monkeypox. Confluent pustules outlining central umbilication, and central ulcero-necrotic area, located in the right labial angle.

Figure 2

Monkeypox. Three pustules with central umbilication on the shaft of the penis.

Monkeypox. Confluent pustules outlining central umbilication, and central ulcero-necrotic area, located in the right labial angle. Monkeypox. Three pustules with central umbilication on the shaft of the penis.

Case 2

The 28-year-old male partner was in a stable relationship with the index case; he was asymptomatic, and reported a “lesion” on the angle of the mouth for a week. He has also been treated for latent syphilis two months before and reported regular use of pre-exposure prophylaxis to prevent contamination with HIV. On physical examination, he was in good general condition, with submental lymphadenopathy (2 cm, indurated, painful and mobile), without genital lesions. He had a 6-mm lesion on the left rima oris with active vesiculopustular borders, central necrotic tissue and an erythematous base (Fig. 3 ).
Figure 3

Monkeypox. Pustule with a depressed and necrotic center located at the left labial angle.

Monkeypox. Pustule with a depressed and necrotic center located at the left labial angle. The hypotheses of herpes simplex and MP were raised. The blood count showed lymphocytosis, HIV serology was negative, and the non-treponemal test (VDRL) was 1/8. The real-time PCR (lesion swab), performed at Fleury Laboratory (São Paulo), confirmed the diagnosis of MP in both individuals. The patients refused to undergo a biopsy of the lesions due to trypanophobia and were treated with paracetamol, instructed to isolate from contacts until the lesions healed, and clean the lesions with antiseptics. After 14 days the lesions regressed leaving residual dyschromia. In a series of 528 MP cases from 16 countries, 98% of those infected were men who had sex with men, with a median age of 38 years. Cutaneous manifestations were identified in 95% of cases. The anogenital area (73%), trunk and limbs (55%), and face (25%) were the most affected areas. Lesions on the palms and soles were reported in only 10% of cases; however, mucous membranes were affected in 41%, and isolated proctitis (14%) was also reported. Fever (62%), painful lymphadenopathy (56%), headache (27%), prostration (41%), and myalgia (31%) were the most frequently reported symptoms. Cutaneous manifestations are evident in MP, and the role of the dermatologist in the early diagnosis of skin lesions is essential in controlling the outbreak. However, in 47% of the cases, the lesions affect up to two regions of the body, which causes some diagnostic confusion, especially with other sexually transmitted diseases, mainly in a group of individuals with risk behavior for sexual transmission.8, 9 MP is a self-limiting disease and the overall mortality has been low in this recent global outbreak (<0.1%). However, very young children and those with immunodeficiencies may have more severe clinical manifestations, such as encephalitis, keratitis, myocarditis, epiglottitis, and pneumonitis; or secondary bacterial infections.2, 9, 10 The screening of the lesions by PCR is becoming widely available in laboratories and hospitals in major urban centers, and the histopathological examination of the lesions may suggest the diagnosis, in addition to help exclude other differentials. Dermatologists should be aware of vesiculopustular lesions in areas of sexual contact and mucous membranes (anogenital and oral regions) as possible manifestations of MP, as well as oligosymptomatic cases or with few cutaneous lesions.

Financial support

None declared.

Authors' contributions

Paula Sian Lopes: Planning of the study, writing and approval of the final version of the manuscript. Gabriela Roncada Haddad: Planning of the study, writing and approval of the final version of the manuscript. Hélio Amante Miot: Planning of the study, writing and approval of the final version of the manuscript.

Conflicts of interest

None declared.
  9 in total

1.  Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022.

Authors:  John P Thornhill; Sapha Barkati; Sharon Walmsley; Juergen Rockstroh; Andrea Antinori; Luke B Harrison; Romain Palich; Achyuta Nori; Iain Reeves; Maximillian S Habibi; Vanessa Apea; Christoph Boesecke; Linos Vandekerckhove; Michal Yakubovsky; Elena Sendagorta; Jose L Blanco; Eric Florence; Davide Moschese; Fernando M Maltez; Abraham Goorhuis; Valerie Pourcher; Pascal Migaud; Sebastian Noe; Claire Pintado; Fabrizio Maggi; Ann-Brit E Hansen; Christian Hoffmann; Jezer I Lezama; Cristina Mussini; AnnaMaria Cattelan; Keletso Makofane; Darrell Tan; Silvia Nozza; Johannes Nemeth; Marina B Klein; Chloe M Orkin
Journal:  N Engl J Med       Date:  2022-07-21       Impact factor: 176.079

2.  As monkeypox goes sexual: a public health perspective.

Authors:  N H Brockmeyer
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-06-22       Impact factor: 9.228

3.  Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases.

Authors:  Alba Català; Petunia Clavo-Escribano; Josep Riera-Monroig; Gemma Martín-Ezquerra; Pablo Fernandez-Gonzalez; Leonor Revelles-Peñas; Ana Simon-Gozalbo; Francisco José Rodríguez-Cuadrado; Vanessa Guilera Castells; Francisco Javier de la Torre Gomar; Alicia Comunión-Artieda; Laura de Fuertes de Vega; José Luis Blanco; Susana Puig; Ángela María García-Miñarro; Esther Fiz Benito; Carlos Muñoz-Santos; Juan Bosco Repiso-Jiménez; Cristina López Llunell; Carmen Ceballos-Rodríguez; Víctor García Rodríguez; Juan Luis Castaño Fernández; Irene Sánchez-Gutiérrez; Ricardo Calvo-López; Emilio Berna-Rico; Belén de Nicolás-Ruanes; Francesca Corella Vicente; Eloy José Tarín Vicente; Laura de la Fernández de la Fuente; Nuria Riera-Martí; Miguel Angel Descalzo-Gallego; Mercè Grau-Perez; Ignacio García-Doval; Irene Fuertes
Journal:  Br J Dermatol       Date:  2022-08-02       Impact factor: 11.113

4.  Monkeypox Genital Lesions.

Authors:  Rita Patrocinio-Jesus; Francesca Peruzzu
Journal:  N Engl J Med       Date:  2022-06-15       Impact factor: 176.079

Review 5.  An Overview of Monkeypox Virus and Its Neuroinvasive Potential.

Authors:  Daniel M Pastula; Kenneth L Tyler
Journal:  Ann Neurol       Date:  2022-08-18       Impact factor: 11.274

6.  Monkeypox virus under COVID-19: Caution for sexual transmission - Correspondence.

Authors:  Fengya Zhu; Liuying Li; Deya Che
Journal:  Int J Surg       Date:  2022-07-07       Impact factor: 13.400

7.  Monkeypox claims new victims: the outbreak in men who have sex with men.

Authors:  Xiaoning Liu; Zheng Zhu; Yun He; Jia Wen Lim; Bethany Lane; Hui Wang; Qiaoli Peng; Liqin Sun; Hongzhou Lu
Journal:  Infect Dis Poverty       Date:  2022-07-23       Impact factor: 10.485

8.  Monkeypox: Another Sexually Transmitted Infection?

Authors:  Alfonso J Rodriguez-Morales; Gustavo Lopardo
Journal:  Pathogens       Date:  2022-06-21

9.  Monkeypox outbreak in Madrid (Spain): Clinical and virological aspects.

Authors:  Eva Orviz; Anabel Negredo; Oskar Ayerdi; Ana Vázquez; Ana Muñoz-Gomez; Sara Monzón; Petunia Clavo; Angel Zaballos; Mar Vera; Patricia Sánchez; Noemi Cabello; Pilar Jiménez; Jorge A Pérez-García; Sarai Varona; Jorge Del Romero; Isabel Cuesta; Alberto Delgado-Iribarren; Montse Torres; Iñigo Sagastagoitia; Gustavo Palacios; Vicente Estrada; Maria Paz Sánchez-Seco
Journal:  J Infect       Date:  2022-07-10       Impact factor: 38.637

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.